These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30259689)

  • 41. Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
    Trani L; Myerson J; Ashley S; Young K; Sheri A; Hubner R; Puglisi M; Popat S; O'Brien ME
    Lung Cancer; 2010 Nov; 70(2):200-4. PubMed ID: 20227784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer.
    Grønberg BH; Sjøblom B; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
    Eur J Clin Nutr; 2019 Jul; 73(7):1069-1076. PubMed ID: 30254241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
    Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
    Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer.
    Suzuki Y; Okamoto T; Fujishita T; Katsura M; Akamine T; Takamori S; Morodomi Y; Tagawa T; Shoji F; Maehara Y
    Lung Cancer; 2016 Nov; 101():92-97. PubMed ID: 27794415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
    Abe H; Takei K; Uematsu T; Tokura Y; Suzuki I; Sakamoto K; Nishihara D; Yamaguchi Y; Mizuno T; Nukui A; Kobayashi M; Kamai T
    Int J Clin Oncol; 2018 Apr; 23(2):338-346. PubMed ID: 29098519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer.
    Jung AR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2019 Aug; 95():95-99. PubMed ID: 31345401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Third-line therapy in advanced non-small cell lung cancer.
    Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
    J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
    Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
    Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Tanabe K
    Target Oncol; 2018 Dec; 13(6):745-755. PubMed ID: 30328067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
    Li A; Niu FY; Han JF; Lou NN; Yang JJ; Zhang XC; Zhou Q; Xie Z; Su J; Zhao N; Huang Y; Wu YL
    Lung Cancer; 2015 Dec; 90(3):375-80. PubMed ID: 26791795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
    Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB
    Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer.
    Mahajan A; Goyal D; Agarwal U; Patil V; Shukla S; Noronha V; Joshi A; Menon N; Prabhash K
    Explor Target Antitumor Ther; 2023; 4(5):896-911. PubMed ID: 37970209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap.
    Ansari E; Chargi N; van Gemert JTM; van Es RJJ; Dieleman FJ; Rosenberg AJWP; Van Cann EM; de Bree R
    Oral Oncol; 2020 Feb; 101():104530. PubMed ID: 31881447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.